GlassScriptPhysician profile
Kathleen Mcelwaney
NPI 1891846630
$3,188.27
in general payments reported to CMS, 2019-2025
35 companies · $484 in 2025
The $484 reported for 2025 was more than what 83% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $579 · 2022: $838 · 2023: $660 · 2024: $627 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.55 |
| Education | $126.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $512.59 | 2022-2025 | Veozah |
| Abbvie INC. | $294.62 | 2021-2023 | |
| Myovant Sciences INC. | $247.42 | 2021-2022 | |
| Sage Therapeutics, LLC | $233.59 | 2021-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $156.68 | 2023-2024 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $156.60 | 2022-2024 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Mayne Pharma Commercial LLC | $135.89 | 2021-2024 | |
| Amgen INC. | $134.38 | 2021-2025 | Evenity, Prolia |
| Daiichi Sankyo INC. | $116.40 | 2021-2022 | |
| Pfizer INC. | $114.16 | 2021-2024 | |
| Organon LLC | $113.41 | 2022-2024 | Nexplanon |
| Evofem Biosciences, INC. | $110.93 | 2021-2022 | |
| Agile Therapeutics, INC. | $99.36 | 2021-2023 | Twirla |
| Therapeuticsmd, INC. | $98.57 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.14 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $81.12 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Radius Health, INC. | $66.60 | 2022-2023 | Tymlos |
| Mylan Pharmaceuticals INC. | $54.68 | 2021-2022 | |
| Exeltis, USA INC. | $51.18 | 2024-2025 | Slynd |
| Lupin INC. | $38.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.17 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.68 | 2025 | Qelbree |
| Coopersurgical, INC. | $23.93 | 2021 | |
| Coloplast Corp | $21.97 | 2025 | |
| Abbott Laboratories | $21.60 | 2023 | Freestyle Libre 3 |
| Northgate Technologies, INC. | $18.46 | 2024 | Stimsite |
| Aspira Women'S Health INC | $17.77 | 2021 | |
| Roche Diagnostics Corporation | $16.98 | 2021 | |
| Exact Sciences Corporation | $16.69 | 2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $15.58 | 2023 | Exparel |
| Shield Therapeutics INC | $14.32 | 2023 | Accrufer |
| Boston Scientific Corporation | $14.03 | 2023 | |
| Radiometer America, INC | $13.19 | 2021 | |
| Medicem INC. | $12.94 | 2021 | |
| Avion Pharmaceuticals | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Mcelwaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.